<DOC>
	<DOCNO>NCT00091442</DOCNO>
	<brief_summary>The purpose study evaluate whether time progression DOXIL docetaxel combination therapy group superior group treat docetaxel monotherapy participant advance breast cancer .</brief_summary>
	<brief_title>A Study Docetaxel Monotherapy DOXIL Docetaxel Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>This randomize ( study medication assign random order ) , active control ( study medication compare available standard care treatment ) , parallel-group ( treatment group treat simultaneously time participant receive one treatment regimen assign ) , open-label ( investigator participant know intervention receive participant ) , multicenter study design determine woman locally advance metastatic breast cancer , previously treat prior anthracycline therapy neoadjuvant ( administration treatment surgery ) adjuvant setting ( administration treatment surgery ) , also disease-free interval least 12 month since end last cytotoxic therapy , would benefit addition DOXIL docetaxel therapy . Approximately 751 participant randomly assign either receive docetaxel monotherapy DOXIL combination docetaxel therapy . Treatment continue disease progression occurrence unacceptable treatment related toxicity . Safety evaluation include assessment adverse event record first study related procedure 30 day last dose medication ; clinical laboratory test test cardiac function ( multiple gate acquisition scan/echocardiogram electrocardiogram ) monitor throughout study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Females locally advance metastatic breast cancer receive prior anthracycline therapy neoadjuvant adjuvant setting , least 12month diseasefree interval since end last cytotoxic therapy , eligible study Participants receive prior hormonal therapy , 1 cytotoxic chemotherapy regimen ( anthracyclines , taxanes , antitubulin agent permit ) , advanced disease Participants normal cardiac function , evidence normal leave ventricular ejection fraction More 1 prior cytotoxic chemotherapy regimen advance breast cancer Treatment advance breast cancer anthracycline , paclitaxel , docetaxel , vinorelbine , vinblastine ( prior treatment advance breast cancer 1 regimen include alkylating agent antimetabolite agent acceptable ) Less 2 month since last dose trastuzumab Less 3 week since last dose tamoxifen fulvestrant , le 1 week since last dose hormonal therapy Radiation area disease within 30 day study enrollment History New York Heart Association Class II great cardiac disease clinical evidence congestive heart failure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Breast Tumors</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Human Mammary Carcinoma</keyword>
	<keyword>Mammary Neoplasms , Human</keyword>
	<keyword>DOXIL</keyword>
	<keyword>Docetaxel</keyword>
</DOC>